Citation Impact
Citing Papers
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation
2007
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
2003 Standout
Metastasis: from dissemination to organ-specific colonization
2009 Standout
Treatment of kidney cancer
2009 StandoutNobel
EGFR Antagonists in Cancer Treatment
2008 Standout
Imatinib Therapy in Clonal Eosinophilic Disorders, Including Systemic Mastocytosis
2004
No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec™/Glivec®)
2003
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
2009 Standout
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
2009 Standout
A view on drug resistance in cancer
2019 StandoutNature
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
2008 StandoutNature
Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib
2010
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Effect of Imatinib Mesylate on Chronic Myelogenous Leukemia Hematopoietic Progenitor Cells
2003
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Molecular monitoring of BCR–ABL as a guide to clinical management in chronic myeloid leukaemia
2005
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Lung Cancer
2008 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
S6K1 determines the metabolic requirements for BCR-ABL survival
2012
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
2006 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Perspectives on the development of a molecularly targeted agent
2002
Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
2010 Standout
Soft-Tissue Sarcomas in Adults
2005 Standout
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
2006 Standout
Cancer Stem Cells: Are We Missing the Target?
2004
Dynamics of chronic myeloid leukaemia
2005 Nature
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
2006
Cancer genes and the pathways they control
2004 Standout
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Chemotherapy and the war on cancer
2005 Standout
Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia
2005
Targeting RAS signalling pathways in cancer therapy
2003 Standout
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal
2010 Nature
Chronic Myelogenous Leukemia
2002
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib
2004
Bisphosphonates in cancer therapy
2007
Hematopoietic Stem-Cell Transplantation
2006 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Met, metastasis, motility and more
2003 Standout
Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance
2012
Revealing the world of RNA interference
2004 StandoutNatureNobel
Applying the discovery of the Philadelphia chromosome
2007
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
2007 StandoutNobel
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
2009 Standout
PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2
2016 StandoutNobel
Angiogenesis as a therapeutic target
2005 StandoutNature
Rational therapeutic intervention in cancer: kinases as drug targets
2002
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Cell Cycle Regulation by Oncogenic Tyrosine Kinases in Myeloid Neoplasias: From Molecular Redox Mechanisms to Health Implications
2008
Specific Killing of Ph+Chronic Myeloid Leukemia Cells by a Lentiviral Vector-Delivered Anti-bcr/ablSmall Hairpin RNA
2003
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Tumour stem cells and drug resistance
2005 Standout
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
2006
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
2004
Biology of Gastrointestinal Stromal Tumors
2004 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
2003
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
2004
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
2004 StandoutScience
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
2006
Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
2011 StandoutScience
Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance
2005
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
Molecular mechanisms of resistance of leukemia to imatinib mesylate
2003
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML
2004
The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML
2002
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
2003
New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
2006
Works of A. Corbin being referenced
Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells
2005
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
2002
Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy
2001